Enteris BioPharma utilizes its Peptelligence® and ProPerma® platforms to build long-term relationships with clients that recognize the business value and patient advantages of orally delivered peptide and small molecule therapeutics.

Peptides and small molecules with poor oral absorption are commonly administered by painful injections, which can lower patient compliance and limit market opportunities for drugmakers. At Enteris, we strive to create innovative therapeutics to improve the lives of patients by developing proprietary, patent-protected oral formulations, which bring game-changing benefits compared to more invasive routes of administration. We partner with clients at various stages of development, from early drug discovery to late-stage clinical, as well as life cycle management of marketed products.

CANDIDATE
FEASIBILITY
PHASE 1
PHASE 2
PHASE 3
TREATMENT
ACTIVE PROGRAMS
KORSUVA™
Cara Therapeutics
(oral difelikefalin)
    • 80%
Pruritus NDD-CKD / AD
Undisclosed
Oral Peptide #1
    • 10%
Metabolic Disorders
Undisclosed Oral
Peptide #2
    • 10%
Metabolic Disorders
Undisclosed Oral
Small Molecule #1
    • 10%
Oncology
Undisclosed Oral
Small Molecule #2
    • 10%
CNS
HISTORICAL PROGRAMS
Oral Calcitonin
    • 90%
Osteoporosis
Oral PTH Analogs
    • 62%
Osteoporosis
Oral GnRH Analogs
    • 25%
Various
Oral GLP-1 Analogs
    • 25%
Type 2 Diabetes
Oral Peptide &
Small Molecules
    • 25%
Various
Oral DACRA Peptides
    • 25%
Metabolic Disorder

ORAL FEASIBILITY PROGRAM

The oral feasibility program is designed to provide clients with a proof-of-concept of the oral bioavailability enhancement that can be achieved from Peptelligence® and ProPerma® formulations.

LEARN MORE

CONTRACT MANUFACTURING

Enteris partners with clients to provide contract manufacturing services for solid oral dosage forms up to phase 3 and commercial scale.

LEARN MORE